MetaVia is trading at $1.46, up +7.35% after the October 14 regular-session close; no verified company-specific catalyst for the after-hours rise surfaced in the search.
- The latest reported company news was MetaVia’s October 13 appointment of Sarah Browne as chief medical officer, which does not clearly explain the move.
- MetaVia fell during the regular session amid a broad market sell-off, but the supplied after-hours move is upward; the market decline does not explain the reversal.